ArticleNature protocols2020
Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay.
Article in Nature protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 285 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
285 citing papers in PubMed.
- Increase in H5N1 vaccine antibodies confers cross-neutralization of highly pathogenic avian influenza H5N1.Nature communications · 2025Trial
- Comparative analysis of neutralization assays performed using live SARS-CoV-2 virus and pseudovirus to assess immunogenicity of a bivalent SARS-CoV-2 protein vaccine in humans.Frontiers in immunology · 2025Trial
- Safety and immunogenicity of heterologous boosting with orally administered aerosolized bivalent adenovirus type-5 vectored COVID-19 vaccine and B.1.1.529 variant adenovirus type-5 vectored COVID-19 vaccine in adults 18 years and older: a randomized, double blinded, parallel controlled trial.Emerging microbes & infections · 2024Trial
- Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways.Emerging microbes & infections · 2026Article
- Article
- mRNA Vaccines Targeting the Conserved SARS-CoV-2 Fusion Machinery Elicit Cross-Variant and Robust Immunity.Vaccines · 2026Article
- R1-32-like public antibodies acquire tolerance to SARS-CoV-2 antigenic drift through somatic hypermutation.PLoS biology · 2026Article
- Photonic-crystal hydraulic manometry quantifies epithelial basal compression for rapid, label-free functional screening.Science advances · 2026Article
- Construction of Synthetic Probiotic Bacteria for In Situ Delivery of Anti-SARS-CoV-2 Nanobodies.Probiotics and antimicrobial proteins · 2026Article
- Optimizing global genomic surveillance for early detection of emerging SARS-CoV-2 variants.Nature communications · 2026Article
- Immunogenic relationship mapping supports a minimal-set trivalent vaccine strategy for broad sarbecovirus protection.Signal transduction and targeted therapy · 2026Article
- Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5.NPJ vaccines · 2026Article
- Intranasal administration of broad-spectrum macrocyclic peptide inhibitor protects against SARS-CoV-2 Omicron variants.Nature communications · 2026Article
- Article
- Trivalent coronavirus vaccines elicit broad-spectrum immunity in mice and attenuate respiratory viral load in golden hamsters.Frontiers in immunology · 2026Article
- Associated uncertainty estimation during the validation process of TCIDFrontiers in immunology · 2026Article
- mRNA vaccine based on high-frequency prevalent antigens provides broad protection against influenza B virus.Molecular therapy. Nucleic acids · 2025Article
- Development ofEmerging microbes & infections · 2025Article
- Longitudinal assessment of immunogenicity of inactivated COVID-19 booster immunization and breakthrough infection in blood donors: A multicenter study from 2021 to 2023.Human vaccines & immunotherapeutics · 2025Article
- A single mutation at position 214 of influenza B hemagglutinin enhances cross-neutralization.Emerging microbes & infections · 2025Article
225 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.
Indexed as
Identifiers
32978602What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.